Fasting-Mimicking Diet Inhibits Autophagy and Synergizes with Chemotherapy to Promote T-Cell-Dependent Leukemia-Free Survival.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro mechanistic study without human data
PubMed 38136414 · doi:10.3390/cancers15245870
What was done
Researchers evaluated the effects of weekly 3-day fasting-mimicking diet (FMD) cycles combined with vincristine chemotherapy in mouse models of BCR-ABL B acute lymphoblastic leukemia (ALL) fed either standard or high-fat diets. They measured autophagy markers via RNA sequencing and protein assays, tested pharmacological (chloroquine) and genetic (ULK1 and ATG9a knockdown) autophagy inhibition, and depleted CD8+ T cells in vivo using anti-CD8 antibodies.
What was found
Combining FMD cycles with vincristine improved survival in high-fat-diet-fed ALL mice and promoted leukemia-free survival in standard-diet-fed mice. Fasting/FMD conditions exacerbated a vincristine-mediated decrease in autophagy markers; chloroquine substitution reproduced the cancer-free survival benefit, and ULK1/ATG9a knockdown potentiated vincristine toxicity in vitro. Administration of anti-CD8 antibodies reversed the survival benefits of FMD plus vincristine in mice. The abstract reports no numerical values, survival times, or effect sizes.
Why it matters
This study outlines a mechanistic basis—combining autophagy suppression with immune activation—by which periodic fasting-mimicking diets may enhance standard chemotherapy in preclinical leukemia models.
Limits
Findings are restricted to cell culture and mouse models, which may not translate to clinical outcomes in human leukemia. The abstract lacks numerical data, exact sample sizes (n), dosing parameters, and statistical measures.
Cited by
- supports In mouse cancer models, cancer-free survival is achieved only when fasting or fasting-mimicking diets are combined with chemotherapy, whereas each intervention alone is almost never curative.